Drug Pipeline

IDE196 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
2
Phase 3
1
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT03947385
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions		 Primary endpoint(s) modified
Active Studies by Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07015190 Neoadjuvant Darovasertib in Primary Uveal Melanoma Uveal Melanoma Recruiting
Phase 2/3
NCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic… Metastatic Uveal Melanoma Active, Not Recruiting
Phase 2
NCT05907954 (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Uveal Melanoma Active, Not Recruiting
Phase 1/2
NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Metastatic Uveal Melanoma Recruiting
Sponsors Running IDE196 Trials
IDEAYA Biosciences (4)
Disease Areas
Melanoma (4) Colorectal Cancer (1)
Get alerts when IDE196 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free